HMGN5 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the HMGN5 gene. This gene-edited pool provides a heterogeneous knockout model, offering robust experimental flexibility without single-cell clonal selection. The polyclonal format preserves genetic diversity while ensuring efficient target gene disruption across the population, making it suitable for pooled functional screens and bulk assays. Researchers can interrogate HMGN5-dependent phenotypes in a near-haploid background, facilitating straightforward genotype-phenotype correlation.
The HAP1 cell line is a near-haploid human myeloid leukemia cell line derived from the KBM-7 chronic myeloid leukemia line, originally isolated from a patient in blast crisis. Its near-haploid karyotype simplifies gene editing, as only one allele needs to be disrupted to achieve functional knockout, enabling efficient generation of homozygous-like knockout populations without laborious screening. HAP1 cells retain key signaling pathways relevant to myeloid biology and are widely used in functional genomics, drug discovery, and cancer research.
HMGN5 encodes a chromatin structural protein that binds nucleosomes to decompact chromatin, thereby modulating transcription, DNA replication, and repair. It acts as a facilitator of transcriptional regulator access, promoting expression of oncogenic targets. HMGN5 is transcriptionally activated by Wnt/??-catenin/TCF signaling and MYC, and functions downstream of growth factors such as EGF and PDGF. It interacts with histones H3 and H4, p53, estrogen receptor ??, and the SWI/SNF complex. Downstream, HMGN5 promotes expression of CCND1, MYC, MMP2, MMP9, CDK4, BCL2, and VEGFA, integrating signals from Wnt/??-catenin, MAPK/ERK, PI3K/AKT, and TGF-?? pathways. Its overexpression is linked to enhanced proliferation, migration, and invasion.
In the HAP1 leukemia context, HMGN5 knockout cells provide a valuable model to dissect its role in myeloid malignancy and broader cancer biology. The near-haploid background ensures that gene disruption directly results in loss of function without compensatory allelic effects, enabling clear assessment of HMGN5-dependent phenotypes. This model is particularly suited for studying chromatin-mediated regulation of oncogenic signaling, as HMGN5 sits at the interface of epigenetic regulation and signal transduction. Its involvement in multiple cancer-relevant pathways makes it a compelling target for investigating mechanisms of tumor progression and therapy resistance.
Researchers can employ these polyclonal knockout cells in diverse assays including Western blotting for HMGN5 protein, RT-qPCR for target genes like CCND1 and MYC, RNA-seq for transcriptomic profiling, and ChIP-qPCR to assess histone modifications. Functional assays such as MTS or colony formation for proliferation, transwell migration/invasion, flow cytometry for cell cycle and apoptosis, and luciferase reporters for Wnt/TCF activity are highly compatible. Co-immunoprecipitation can validate interactions with nucleosomes or signaling proteins, while phospho-ERK/AKT analysis enables pathway interrogation. This knockout model supports investigations into chromatin dynamics, drug resistance, and metastatic mechanisms. For further information, please contact Ascent Research.
